RecruitingPhase 2NCT07125872

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Sponsor

ImmunityBio, Inc.

Enrollment

20 participants

Start Date

Nov 11, 2025

Study Type

INTERVENTIONAL

Conditions

Relapsed B-Cell Non Hodgkin Lymphoma

Summary

Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing treatments for people with B-cell Non-Hodgkin Lymphoma (a type of blood cancer) that has returned or is no longer responding to prior therapy. **You may be eligible if...** - You are over 18 years old - You have confirmed B-cell Non-Hodgkin Lymphoma (by biopsy or flow cytometry) - Your lymphoma has relapsed or is refractory (not responding) to at least one prior treatment - You are in adequate overall health to participate **You may NOT be eligible if...** - You have primary CNS lymphoma, chronic lymphocytic leukemia (CLL), or Burkitt lymphoma - Your lymphoma has spread to the brain or spinal fluid - You have serious active infections or other significant medical conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCD19 t-haNK- IV Administration

N-803 Subcutaneous (SQ): N-803 is a novel IL-15 superagonist immunotherapy administered subcutaneously. It is designed to enhance the proliferation and activation of natural killer (NK) cells and CD8+ T cells without stimulating regulatory T cells. N-803 SQ differs from other cytokine therapies due to its improved pharmacokinetic profile, enhanced in vivo activity, and reduced toxicity. CD19-Directed Therapies: CD19-targeted therapies, are biologic agents specifically designed to recognize and eliminate CD19-expressing B-cell malignancies. These therapies differ from traditional chemotherapy or small molecule inhibitors by leveraging the patient's immune system to achieve targeted cytotoxicity. Their mechanism of action involves direct binding to the CD19 antigen on malignant B cells, leading to immune-mediated cell death.

Locations(2)

Dr. Jackie Thomson Inc

Johannesburg, South Africa

Albert Cellular Therapy

Pretoria, South Africa

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07125872